sector
Life-sciences AI infrastructure depends on which notebook methods, sample records, instrument files, omics runs and automation logs can cross into AI use while preserving source ownership, permissions, reviewer action and validation evidence.
INFRALife sciencesGLOBAL
2026-06-01
Pharma and biotech R&D AI should be evaluated as an experiment-capacity allocator: the model earns budget when it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots.
MODELSLife sciencesGLOBAL
2026-06-01
Clinical-trial and regulatory-operations AI agents should be evaluated by the handoff they improve: accepted trial match, closed EDC query, inspection-ready eTMF document, clean registry/results update, usable endpoint record, safety-narrative QC or agency-response package.
AGENTSLife sciencesGLOBAL
2026-06-01
Pharmacovigilance and medical-affairs agents should preserve safety-to-label truth: AI-touched case facts, signal work items, label rationales, acceptor, downstream safety action and approved response boundary.
AGENTSLife sciencesGLOBAL
2026-06-01